We’re thrilled to announce that Biocytogen will be attending the 2025 ASH Annual Meeting & Exposition, taking place December 6–9 in Orlando, Florida! Join us for four days of impactful presentations, cutting-edge poster sessions, scientific symposia, and an engaging exhibit hall experience. This premier event will showcase the latest breakthroughs in drug development, clinical advances, and regulatory science, while offering opportunities to connect with leaders in hematology and related fields. Visit the Biocytogen booth to meet our team and explore our innovative platforms, including genetically engineered animal models and advanced antibody discovery technologies. Learn how we support research in hematopoietic diseases, immunotherapy development, and the identification and validation of therapeutic antibodies targeting the immune system. We look forward to seeing you in Orlando!
What is ASH 2025?
The 2025 ASH (American Society of Hematology) Annual Meeting is the premier global gathering for the hematology community, bringing together cutting-edge scientific research, advanced clinical education, dynamic networking, and professional development opportunities. From groundbreaking discoveries in basic science to practical approaches in patient care. Attendees will gain insights into the latest developments in drug discovery, clinical advancements, and regulatory trends while engaging with thought leaders and experts in life sciences.
Event Overview
Date: December 6th-9th, 2025
Venue: Orange County Convention Center. 9800 International Dr. Orlando, FL.
Event Schedule
For more information, please refer to ASH 2025 Schedule .
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We can’t wait to see you in Orlando, Florida!
